<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Orthocell Ltd — News on 6ix</title>
<link>https://6ix.com/company/orthocell-ltd</link>
<description>Latest news and press releases for Orthocell Ltd on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 03:31:07 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/orthocell-ltd" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683667bf78dffbe2df15e743.webp</url>
<title>Orthocell Ltd</title>
<link>https://6ix.com/company/orthocell-ltd</link>
</image>
<item>
<title>Compelling 90% Success Rate for Remplir in Real World Study</title>
<link>https://6ix.com/company/orthocell-ltd/news/compelling-90percent-success-rate-for-remplir-in-real-world-study</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/compelling-90percent-success-rate-for-remplir-in-real-world-study</guid>
<pubDate>Tue, 28 Apr 2026 03:31:07 GMT</pubDate>
<description>Compelling 90% Success Rate for Remplir in Real World Study</description>
</item>
<item>
<title>Q3 FY26 Investor Presentation</title>
<link>https://6ix.com/company/orthocell-ltd/news/q3-fy26-investor-presentation</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/q3-fy26-investor-presentation</guid>
<pubDate>Mon, 20 Apr 2026 03:26:05 GMT</pubDate>
<description>Q3 FY26 Investor Presentation</description>
</item>
<item>
<title>First Surgical Use of Remplir in US Department of Defense</title>
<link>https://6ix.com/company/orthocell-ltd/news/first-surgical-use-of-remplir-in-us-department-of-defense</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/first-surgical-use-of-remplir-in-us-department-of-defense</guid>
<pubDate>Fri, 17 Apr 2026 03:22:05 GMT</pubDate>
<description>First Surgical Use of Remplir in US Department of Defense</description>
</item>
<item>
<title>OCC Secures Access to 221 U.S. Military Medical Centres</title>
<link>https://6ix.com/company/orthocell-ltd/news/occ-secures-access-to-221-us-military-medical-centres</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/occ-secures-access-to-221-us-military-medical-centres</guid>
<pubDate>Wed, 15 Apr 2026 03:21:04 GMT</pubDate>
<description>OCC Secures Access to 221 U.S. Military Medical Centres</description>
</item>
<item>
<title>Remplir Used in 23 Surgeries in Ukrainian soldiers</title>
<link>https://6ix.com/company/orthocell-ltd/news/remplir-used-in-23-surgeries-in-ukrainian-soldiers</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/remplir-used-in-23-surgeries-in-ukrainian-soldiers</guid>
<pubDate>Wed, 18 Mar 2026 03:18:03 GMT</pubDate>
<description>Remplir Used in 23 Surgeries in Ukrainian soldiers</description>
</item>
<item>
<title>Orthocell Appoints UK Distributor for Remplir</title>
<link>https://6ix.com/company/orthocell-ltd/news/orthocell-appoints-uk-distributor-for-remplir</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/orthocell-appoints-uk-distributor-for-remplir</guid>
<pubDate>Tue, 10 Mar 2026 02:29:04 GMT</pubDate>
<description>Orthocell Appoints UK Distributor for Remplir</description>
</item>
<item>
<title>Appendix 4D & Half-Year Financial Report</title>
<link>https://6ix.com/company/orthocell-ltd/news/appendix-4d-and-half-year-financial-report-47</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/appendix-4d-and-half-year-financial-report-47</guid>
<pubDate>Tue, 24 Feb 2026 03:23:16 GMT</pubDate>
<description>Appendix 4D & Half-Year Financial Report</description>
</item>
<item>
<title>Orthocell Receives $3.0m R&D Tax Refund</title>
<link>https://6ix.com/company/orthocell-ltd/news/orthocell-receives-dollar30m-randd-tax-refund</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/orthocell-receives-dollar30m-randd-tax-refund</guid>
<pubDate>Wed, 18 Feb 2026 07:17:03 GMT</pubDate>
<description>Orthocell Receives $3.0m R&D Tax Refund</description>
</item>
<item>
<title>US Market and Operational Update</title>
<link>https://6ix.com/company/orthocell-ltd/news/us-market-and-operational-update</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/us-market-and-operational-update</guid>
<pubDate>Mon, 02 Feb 2026 03:23:07 GMT</pubDate>
<description>US Market and Operational Update</description>
</item>
<item>
<title>Quarterly Activity Report & Appendix 4C</title>
<link>https://6ix.com/company/orthocell-ltd/news/quarterly-activity-report-and-appendix-4c-5</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/quarterly-activity-report-and-appendix-4c-5</guid>
<pubDate>Mon, 19 Jan 2026 03:28:13 GMT</pubDate>
<description>Quarterly Activity Report & Appendix 4C</description>
</item>
<item>
<title>Orthocell Posts Seventh Straight Record Revenue Quarter</title>
<link>https://6ix.com/company/orthocell-ltd/news/orthocell-posts-seventh-straight-record-revenue-quarter</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/orthocell-posts-seventh-straight-record-revenue-quarter</guid>
<pubDate>Tue, 06 Jan 2026 03:54:14 GMT</pubDate>
<description>Orthocell Posts Seventh Straight Record Revenue Quarter</description>
</item>
<item>
<title>Orthocell Hits US Milestone - 100 Remplir Units Sold.</title>
<link>https://6ix.com/company/orthocell-ltd/news/orthocell-hits-us-milestone-100-remplir-units-sold</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/orthocell-hits-us-milestone-100-remplir-units-sold</guid>
<pubDate>Thu, 18 Dec 2025 04:03:11 GMT</pubDate>
<description>Orthocell Hits US Milestone - 100 Remplir Units Sold.</description>
</item>
<item>
<title>Remplir Regulatory Application for US$750m EU-UK Market</title>
<link>https://6ix.com/company/orthocell-ltd/news/remplir-regulatory-application-for-usdollar750m-eu-uk-market</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/remplir-regulatory-application-for-usdollar750m-eu-uk-market</guid>
<pubDate>Mon, 15 Dec 2025 03:26:07 GMT</pubDate>
<description>Remplir Regulatory Application for US$750m EU-UK Market</description>
</item>
<item>
<title>First Commercial Sales of Remplir Achieved in Hong Kong</title>
<link>https://6ix.com/company/orthocell-ltd/news/first-commercial-sales-of-remplir-achieved-in-hong-kong</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/first-commercial-sales-of-remplir-achieved-in-hong-kong</guid>
<pubDate>Wed, 10 Dec 2025 03:39:15 GMT</pubDate>
<description>First Commercial Sales of Remplir Achieved in Hong Kong</description>
</item>
<item>
<title>Remplir™ Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum with ~100 Surgeries Now Performed with Multiple Surgeons Nationwide</title>
<link>https://6ix.com/company/orthocell-ltd/news/remplir-nerve-sparing-prostate-cancer-055200191</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/remplir-nerve-sparing-prostate-cancer-055200191</guid>
<pubDate>Thu, 20 Nov 2025 05:52:00 GMT</pubDate>
<description>Orthocell Limited (ASX: OCC) is pleased to announce adoption of Remplir™ by Australian urologists is accelerating with the product increasingly being used during prostate cancer surgery in a promising new application aimed at reducing post-surgical complications from peripheral nerve injury. Remplir has now been used in ~100 surgical cases to assist in improving recovery of erectile function and urinary continence post-surgery.</description>
</item>
<item>
<title>Remplir gains momentum in nerve-sparing prostate surgery</title>
<link>https://6ix.com/company/orthocell-ltd/news/remplir-gains-momentum-in-nerve-sparing-prostate-surgery</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/remplir-gains-momentum-in-nerve-sparing-prostate-surgery</guid>
<pubDate>Thu, 20 Nov 2025 03:23:17 GMT</pubDate>
<description>Remplir gains momentum in nerve-sparing prostate surgery</description>
</item>
<item>
<title>2nd Distributor in Canada, Entire $75m Market Now Covered</title>
<link>https://6ix.com/company/orthocell-ltd/news/2nd-distributor-in-canada-entire-dollar75m-market-now-covered</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/2nd-distributor-in-canada-entire-dollar75m-market-now-covered</guid>
<pubDate>Wed, 05 Nov 2025 03:20:10 GMT</pubDate>
<description>2nd Distributor in Canada, Entire $75m Market Now Covered</description>
</item>
<item>
<title>Remplir Launches in Hong Kong with First Surgical Case</title>
<link>https://6ix.com/company/orthocell-ltd/news/remplir-launches-in-hong-kong-with-first-surgical-case</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/remplir-launches-in-hong-kong-with-first-surgical-case</guid>
<pubDate>Mon, 03 Nov 2025 03:33:18 GMT</pubDate>
<description>Remplir Launches in Hong Kong with First Surgical Case</description>
</item>
<item>
<title>HK Distributor Signed as Remplir Expands in the Asian Market</title>
<link>https://6ix.com/company/orthocell-ltd/news/hk-distributor-signed-as-remplir-expands-in-the-asian-market</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/hk-distributor-signed-as-remplir-expands-in-the-asian-market</guid>
<pubDate>Wed, 29 Oct 2025 02:18:19 GMT</pubDate>
<description>HK Distributor Signed as Remplir Expands in the Asian Market</description>
</item>
<item>
<title>OCC Secures Rights to High-Value Bone Regeneration Tech</title>
<link>https://6ix.com/company/orthocell-ltd/news/occ-secures-rights-to-high-value-bone-regeneration-tech</link>
<guid isPermaLink="true">https://6ix.com/company/orthocell-ltd/news/occ-secures-rights-to-high-value-bone-regeneration-tech</guid>
<pubDate>Mon, 20 Oct 2025 02:17:06 GMT</pubDate>
<description>OCC Secures Rights to High-Value Bone Regeneration Tech</description>
</item>
</channel>
</rss>